Methods for Association Analysis and Meta‐Analysis of Rare Variants in Families

Advances in exome sequencing and the development of exome genotyping arrays are enabling explorations of association between rare coding variants and complex traits. To ensure power for these rare variant analyses, a variety of association tests that group variants by gene or functional unit have been proposed. Here, we extend these tests to family‐based studies. We develop family‐based burden tests, variable frequency threshold tests and sequence kernel association tests. Through simulations, we compare the performance of different tests. We describe situations where family‐based studies provide greater power than studies of unrelated individuals to detect rare variants associated with moderate to large changes in trait values. Broadly speaking, we find that when sample sizes are limited and only a modest fraction of all trait‐associated variants can be identified, family samples are more powerful. Finally, we illustrate our approach by analyzing the relationship between coding variants and levels of high‐density lipoprotein (HDL) cholesterol in 11,556 individuals from the HUNT and SardiNIA studies, demonstrating association for coding variants in the APOC3, CETP, LIPC, LIPG, and LPL genes and illustrating the value of family samples, meta‐analysis, and gene‐level tests. Our methods are implemented in freely available C++ code.     

Pathway‐Based Approaches for Sequencing‐Based Genome‐Wide Association Studies

For analyzing complex trait association with sequencing data, most current studies test aggregated effects of variants in a gene or genomic region. Although gene‐based tests have insufficient power even for moderately sized samples, pathway‐based analyses combine information across multiple genes in biological pathways and may offer additional insight. However, most existing pathway association methods are originally designed for genome‐wide association studies, and are not comprehensively evaluated for sequencing data. Moreover, region‐based rare variant association methods, although potentially applicable to pathway‐based analysis by extending their region definition to gene sets, have never been rigorously tested. In the context of exome‐based studies, we use simulated and real datasets to evaluate pathway‐based association tests. Our simulation strategy adopts a genome‐wide genetic model that distributes total genetic effects hierarchically into pathways, genes, and individual variants, allowing the evaluation of pathway‐based methods with realistic quantifiable assumptions on the underlying genetic architectures. The results show that, although no single pathway‐based association method offers superior performance in all simulated scenarios, a modification of Gene Set Enrichment Analysis approach using statistics from single‐marker tests without gene‐level collapsing (weighted Kolmogrov‐Smirnov [WKS]‐Variant method) is consistently powerful. Interestingly, directly applying rare variant association tests (e.g., sequence kernel association test) to pathway analysis offers a similar power, but its results are sensitive to assumptions of genetic architecture. We applied pathway association analysis to an exome‐sequencing data of the chronic obstructive pulmonary disease, and found that the WKS‐Variant method confirms associated genes previously published.     

Longitudinal SNP‐set association analysis of quantitative phenotypes

Many genetic epidemiological studies collect repeated measurements over time. This design not only provides a more accurate assessment of disease condition, but allows us to explore the genetic influence on disease development and progression. Thus, it is of great interest to study the longitudinal contribution of genes to disease susceptibility. Most association testing methods for longitudinal phenotypes are developed for single variant, and may have limited power to detect association, especially for variants with low minor allele frequency. We propose Longitudinal SNP‐set/sequence kernel association test (LSKAT), a robust, mixed‐effects method for association testing of rare and common variants with longitudinal quantitative phenotypes. LSKAT uses several random effects to account for the within‐subject correlation in longitudinal data, and allows for adjustment for both static and time‐varying covariates. We also present a longitudinal trait burden test (LBT), where we test association between the trait and the burden score in linear mixed models. In simulation studies, we demonstrate that LBT achieves high power when variants are almost all deleterious or all protective, while LSKAT performs well in a wide range of genetic models. By making full use of trait values from repeated measures, LSKAT is more powerful than several tests applied to a single measurement or average over all time points. Moreover, LSKAT is robust to misspecification of the covariance structure. We apply the LSKAT and LBT methods to detect association with longitudinally measured body mass index in the Framingham Heart Study, where we are able to replicate association with a circadian gene NR1D2.     

Region‐based association tests for sequencing data on survival traits

Family‐based designs enriched with affected subjects and disease associated variants can increase statistical power for identifying functional rare variants. However, few rare variant analysis approaches are available for time‐to‐event traits in family designs and none of them applicable to the X chromosome. We developed novel pedigree‐based burden and kernel association tests for time‐to‐event outcomes with right censoring for pedigree data, referred to FamRATS (family‐based rare variant association tests for survival traits). Cox proportional hazard models were employed to relate a time‐to‐event trait with rare variants with flexibility to encompass all ranges and collapsing of multiple variants. In addition, the robustness of violating proportional hazard assumptions was investigated for the proposed and four current existing tests, including the conventional population‐based Cox proportional model and the burden, kernel, and sum of squares statistic (SSQ) tests for family data. The proposed tests can be applied to large‐scale whole‐genome sequencing data. They are appropriate for the practical use under a wide range of misspecified Cox models, as well as for population‐based, pedigree‐based, or hybrid designs. In our extensive simulation study and data example, we showed that the proposed kernel test is the most powerful and robust choice among the proposed burden test and the existing four rare variant survival association tests. When applied to the Diabetes Heart Study, the proposed tests found exome variants of the JAK1 gene on chromosome 1 showed the most significant association with age at onset of type 2 diabetes from the exome‐wide analysis.     

Efficient unified rare variant association test by modeling the population genetic distribution in case‐control studies

Recent advancements in next‐generation DNA sequencing technologies have made it plausible to study the association of rare variants with complex diseases. Due to the low frequency, rare variants need to be aggregated in association tests to achieve adequate power with reasonable sample sizes. Hierarchical modeling/kernel machine methods have gained popularity among many available methods for testing a set of rare variants collectively. Here, we propose a new score statistic based on a hierarchical model by additionally modeling the distribution of rare variants under the case‐control study design. Results from extensive simulation studies show that the proposed method strikes a balance between robustness and power and outperforms several popular rare‐variant association tests. We demonstrate the performance of our method using the Dallas Heart Study.     

Detecting association of rare and common variants based on cross‐validation prediction error

Despite the extensive discovery of disease‐associated common variants, much of the genetic contribution to complex traits remains unexplained. Rare variants may explain additional disease risk or trait variability. Although sequencing technology provides a supreme opportunity to investigate the roles of rare variants in complex diseases, detection of these variants in sequencing‐based association studies presents substantial challenges. In this article, we propose novel statistical tests to test the association between rare and common variants in a genomic region and a complex trait of interest based on cross‐validation prediction error (PE). We first propose a PE method based on Ridge regression. Based on PE, we also propose another two tests PE‐WS and PE‐TOW by testing a weighted combination of variants with two different weighting schemes. PE‐WS is the PE version of the test based on the weighted sum statistic (WS) and PE‐TOW is the PE version of the test based on the optimally weighted combination of variants (TOW). Using extensive simulation studies, we are able to show that (1) PE‐TOW and PE‐WS are consistently more powerful than TOW and WS, respectively, and (2) PE is the most powerful test when causal variants contain both common and rare variants.     

A powerful association test of multiple genetic variants using a random‐effects model

There is an emerging interest in sequencing‐based association studies of multiple rare variants. Most association tests suggested in the literature involve collapsing rare variants with or without weighting. Recently, a variance‐component score test [sequence kernel association test (SKAT)] was proposed to address the limitations of collapsing method. Although SKAT was shown to outperform most of the alternative tests, its applications and power might be restricted and influenced by missing genotypes. In this paper, we suggest a new method based on testing whether the fraction of causal variants in a region is zero. The new association test, T _REM, is derived from a random‐effects model and allows for missing genotypes, and the choice of weighting function is not required when common and rare variants are analyzed simultaneously. We performed simulations to study the type I error rates and power of four competing tests under various conditions on the sample size, genotype missing rate, variant frequency, effect directionality, and the number of non‐causal rare variant and/or causal common variant. The simulation results showed that T _REM was a valid test and less sensitive to the inclusion of non‐causal rare variants and/or low effect common variants or to the presence of missing genotypes. When the effects were more consistent in the same direction, T _REM also had better power performance. Finally, an application to the Shanghai Breast Cancer Study showed that rare causal variants at the FGFR2 gene were detected by T _REM and SKAT, but T _REM produced more consistent results for different sets of rare and common variants. Copyright © 2013 John Wiley & Sons, Ltd.     

Leveraging population information in family‐based rare variant association analyses of quantitative traits

Confounding due to population substructure is always a concern in genetic association studies. Although methods have been proposed to adjust for population stratification in the context of common variation, it is unclear how well these approaches will work when interrogating rare variation. Family‐based association tests can be constructed that are robust to population stratification. For example, when considering a quantitative trait, a linear model can be used that decomposes genetic effects into between‐ and within‐family components and a test of the within‐family component is robust to population stratification. However, this within‐family test ignores between‐family information potentially leading to a loss of power. Here, we propose a family‐based two‐stage rare‐variant test for quantitative traits. We first construct a weight for each variant within a gene, or other genetic unit, based on score tests of between‐family effect parameters. These weights are then used to combine variants using score tests of within‐family effect parameters. Because the between‐family and within‐family tests are orthogonal under the null hypothesis, this two‐stage approach can increase power while still maintaining validity. Using simulation, we show that this two‐stage test can significantly improve power while correctly maintaining type I error. We further show that the two‐stage approach maintains the robustness to population stratification of the within‐family test and we illustrate this using simulations reflecting samples composed of continental and closely related subpopulations.     

Two‐phase designs for joint quantitative‐trait‐dependent and genotype‐dependent sampling in post‐GWAS regional sequencing

We evaluate two‐phase designs to follow‐up findings from genome‐wide association study (GWAS) when the cost of regional sequencing in the entire cohort is prohibitive. We develop novel expectation‐maximization‐based inference under a semiparametric maximum likelihood formulation tailored for post‐GWAS inference. A GWAS‐SNP (where SNP is single nucleotide polymorphism) serves as a surrogate covariate in inferring association between a sequence variant and a normally distributed quantitative trait (QT). We assess test validity and quantify efficiency and power of joint QT‐SNP‐dependent sampling and analysis under alternative sample allocations by simulations. Joint allocation balanced on SNP genotype and extreme‐QT strata yields significant power improvements compared to marginal QT‐ or SNP‐based allocations. We illustrate the proposed method and evaluate the sensitivity of sample allocation to sampling variation using data from a sequencing study of systolic blood pressure.     

Generalized estimating equations for genome‐wide association studies using longitudinal phenotype data

Many longitudinal cohort studies have both genome‐wide measures of genetic variation and repeated measures of phenotypes and environmental exposures. Genome‐wide association study analyses have typically used only cross‐sectional data to evaluate quantitative phenotypes and binary traits. Incorporation of repeated measures may increase power to detect associations, but also requires specialized analysis methods. Here, we discuss one such method—generalized estimating equations (GEE)—in the contexts of analysis of main effects of rare genetic variants and analysis of gene‐environment interactions. We illustrate the potential for increased power using GEE analyses instead of cross‐sectional analyses. We also address challenges that arise, such as the need for small‐sample corrections when the minor allele frequency of a genetic variant and/or the prevalence of an environmental exposure is low. To illustrate methods for detection of gene‐drug interactions on a genome‐wide scale, using repeated measures data, we conduct single‐study analyses and meta‐analyses across studies in three large cohort studies participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium—the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, and the Rotterdam Study. Copyright © 2014 John Wiley & Sons, Ltd.     

Meta‐Analysis of Rare Variant Association Tests in Multiethnic Populations

Several methods have been proposed to increase power in rare variant association testing by aggregating information from individual rare variants (MAF < 0.005). However, how to best combine rare variants across multiple ethnicities and the relative performance of designs using different ethnic sampling fractions remains unknown. In this study, we compare the performance of several statistical approaches for assessing rare variant associations across multiple ethnicities. We also explore how different ethnic sampling fractions perform, including single‐ethnicity studies and studies that sample up to four ethnicities. We conducted simulations based on targeted sequencing data from 4,611 women in four ethnicities (African, European, Japanese American, and Latina). As with single‐ethnicity studies, burden tests had greater power when all causal rare variants were deleterious, and variance component‐based tests had greater power when some causal rare variants were deleterious and some were protective. Multiethnic studies had greater power than single‐ethnicity studies at many loci, with inclusion of African Americans providing the largest impact. On average, studies including African Americans had as much as 20% greater power than equivalently sized studies without African Americans. This suggests that association studies between rare variants and complex disease should consider including subjects from multiple ethnicities, with preference given to genetically diverse groups.     

A Unified Mixed‐Effects Model for Rare‐Variant Association in Sequencing Studies

For rare‐variant association analysis, due to extreme low frequencies of these variants, it is necessary to aggregate them by a prior set (e.g., genes and pathways) in order to achieve adequate power. In this paper, we consider hierarchical models to relate a set of rare variants to phenotype by modeling the effects of variants as a function of variant characteristics while allowing for variant‐specific effect (heterogeneity). We derive a set of two score statistics, testing the group effect by variant characteristics and the heterogeneity effect. We make a novel modification to these score statistics so that they are independent under the null hypothesis and their asymptotic distributions can be derived. As a result, the computational burden is greatly reduced compared with permutation‐based tests. Our approach provides a general testing framework for rare variants association, which includes many commonly used tests, such as the burden test [Li and Leal, 2008] and the sequence kernel association test [Wu et al., 2011], as special cases. Furthermore, in contrast to these tests, our proposed test has an added capacity to identify which components of variant characteristics and heterogeneity contribute to the association. Simulations under a wide range of scenarios show that the proposed test is valid, robust, and powerful. An application to the Dallas Heart Study illustrates that apart from identifying genes with significant associations, the new method also provides additional information regarding the source of the association. Such information may be useful for generating hypothesis in future studies.     

BinomiRare: A robust test of the association of a rare variant with a disease for pooled analysis and meta‐analysis,with application to the HCHS/SOL

Most regression‐based tests of the association between a low‐count variant and a binary outcome do not protect type 1 error, especially when tests are rejected based on a very low significance threshold. Noted exception is the Firth test. However, it was recently shown that in meta‐analyzing multiple studies all asymptotic, regression‐based tests, including the Firth, may not control type 1 error in some settings, and the Firth test may suffer a substantial loss of power. The problem is exacerbated when the case‐control proportions differ between studies. I propose the BinomiRare exact test that circumvents the calibration problems of regression‐based estimators. It quantifies the strength of association between the variant and the disease outcome based on the departure of the number of diseased individuals carrying the variant from the expected distribution of disease probability, under the null hypothesis of no association between the disease outcome and the rare variant. I provide a meta‐analytic strategy to combine tests across multiple cohorts, which requires that each cohort provides the disease probabilities of all carriers of the variant in question, and the number of diseased individuals among the carriers. I show that BinomiRare controls type 1 error in meta‐analysis even when the case‐control proportions differ between the studies, and does not lose power compared to pooled analysis. I demonstrate the test in studying the association of rare variants with asthma in the Hispanic Community Health Study/Study of Latinos.     

Generalization of Rare Variant Association Tests for Longitudinal Family Studies

Given the functional relevance of many rare variants, their identification is frequently critical for dissecting disease etiology. Functional variants are likely to be aggregated in family studies enriched with affected members, and this aggregation increases the statistical power to detect rare variants associated with a trait of interest. Longitudinal family studies provide additional information for identifying genetic and environmental factors associated with disease over time. However, methods to analyze rare variants in longitudinal family data remain fairly limited. These methods should be capable of accounting for different sources of correlations and handling large amounts of sequencing data efficiently. To identify rare variants associated with a phenotype in longitudinal family studies, we extended pedigree‐based burden (BT) and kernel (KS) association tests to genetic longitudinal studies. Generalized estimating equation (GEE) approaches were used to generalize the pedigree‐based BT and KS to multiple correlated phenotypes under the generalized linear model framework, adjusting for fixed effects of confounding factors. These tests accounted for complex correlations between repeated measures of the same phenotype (serial correlations) and between individuals in the same family (familial correlations). We conducted comprehensive simulation studies to compare the proposed tests with mixed‐effects models and marginal models, using GEEs under various configurations. When the proposed tests were applied to data from the Diabetes Heart Study, we found exome variants of POMGNT1 and JAK1 genes were associated with type 2 diabetes.     

Adjusted Sequence Kernel Association Test for Rare Variants Controlling for Cryptic and Family Relatedness

Recent progress in sequencing technologies makes it possible to identify rare and unique variants that may be associated with complex traits. However, the results of such efforts depend crucially on the use of efficient statistical methods and study designs. Although family‐based designs might enrich a data set for familial rare disease variants, most existing rare variant association approaches assume independence of all individuals. We introduce here a framework for association testing of rare variants in family‐based designs. This framework is an adaptation of the sequence kernel association test (SKAT) which allows us to control for family structure. Our adjusted SKAT (ASKAT) combines the SKAT approach and the factored spectrally transformed linear mixed models (FaST‐LMMs) algorithm to capture family effects based on a LMM incorporating the realized proportion of the genome that is identical by descent between pairs of individuals, and using restricted maximum likelihood methods for estimation. In simulation studies, we evaluated type I error and power of this proposed method and we showed that regardless of the level of the trait heritability, our approach has good control of type I error and good power. Since our approach uses FaST‐LMM to calculate variance components for the proposed mixed model, ASKAT is reasonably fast and can analyze hundreds of thousands of markers. Data from the UK twins consortium are presented to illustrate the ASKAT methodology.     

Evaluating the Calibration and Power of Three Gene‐Based Association Tests of Rare Variants for the X Chromosome

Although genome‐wide association studies (GWAS) have identified thousands of trait‐associated genetic variants, there are relatively few findings on the X chromosome. For analysis of low‐frequency variants (minor allele frequency <5%), investigators can use region‐ or gene‐based tests where multiple variants are analyzed jointly to increase power. To date, there are no gene‐based tests designed for association testing of low‐frequency variants on the X chromosome. Here we propose three gene‐based tests for the X chromosome: burden, sequence kernel association test (SKAT), and optimal unified SKAT (SKAT‐O). Using simulated case‐control and quantitative trait (QT) data, we evaluate the calibration and power of these tests as a function of (1) male:female sample size ratio; and (2) coding of haploid male genotypes for variants under X‐inactivation. For case‐control studies, all three tests are reasonably well‐calibrated for all scenarios we evaluated. As expected, power for gene‐based tests depends on the underlying genetic architecture of the genomic region analyzed. Studies with more (haploid) males are generally less powerful due to decreased number of chromosomes. Power generally is slightly greater when the coding scheme for male genotypes matches the true underlying model, but the power loss for misspecifying the (generally unknown) model is small. For QT studies, type I error and power results largely mirror those for binary traits. We demonstrate the use of these three gene‐based tests for X‐chromosome association analysis in simulated data and sequencing data from the Genetics of Type 2 Diabetes (GoT2D) study.     

A Fast and Noise‐Resilient Approach to Detect Rare‐Variant Associations With Deep Sequencing Data for Complex Disorders

Next generation sequencing technology has enabled the paradigm shift in genetic association studies from the common disease/common variant to common disease/rare‐variant hypothesis. Analyzing individual rare variants is known to be underpowered; therefore association methods have been developed that aggregate variants across a genetic region, which for exome sequencing is usually a gene. The foreseeable widespread use of whole genome sequencing poses new challenges in statistical analysis. It calls for new rare‐variant association methods that are statistically powerful, robust against high levels of noise due to inclusion of noncausal variants, and yet computationally efficient. We propose a simple and powerful statistic that combines the disease‐associated P‐values of individual variants using a weight that is the inverse of the expected standard deviation of the allele frequencies under the null. This approach, dubbed as Sigma‐P method, is extremely robust to the inclusion of a high proportion of noncausal variants and is also powerful when both detrimental and protective variants are present within a genetic region. The performance of the Sigma‐P method was tested using simulated data based on realistic population demographic and disease models and its power was compared to several previously published methods. The results demonstrate that this method generally outperforms other rare‐variant association methods over a wide range of models. Additionally, sequence data on the ANGPTL family of genes from the Dallas Heart Study were tested for associations with nine metabolic traits and both known and novel putative associations were uncovered using the Sigma‐P method.     

Recommended Joint and Meta‐Analysis Strategies for Case‐Control Association Testing of Single Low‐Count Variants

In genome‐wide association studies of binary traits, investigators typically use logistic regression to test common variants for disease association within studies, and combine association results across studies using meta‐analysis. For common variants, logistic regression tests are well calibrated, and meta‐analysis of study‐specific association results is only slightly less powerful than joint analysis of the combined individual‐level data. In recent sequencing and dense chip based association studies, investigators increasingly test low‐frequency variants for disease association. In this paper, we seek to (1) identify the association test with maximal power among tests with well controlled type I error rate and (2) compare the relative power of joint and meta‐analysis tests. We use analytic calculation and simulation to compare the empirical type I error rate and power of four logistic regression based tests: Wald, score, likelihood ratio, and Firth bias‐corrected. We demonstrate for low‐count variants (roughly minor allele count [MAC] < 400) that: (1) for joint analysis, the Firth test has the best combination of type I error and power; (2) for meta‐analysis of balanced studies (equal numbers of cases and controls), the score test is best, but is less powerful than Firth test based joint analysis; and (3) for meta‐analysis of sufficiently unbalanced studies, all four tests can be anti‐conservative, particularly the score test. We also establish MAC as the key parameter determining test calibration for joint and meta‐analysis.     

A rare variant association test in family‐based designs and non‐normal quantitative traits

Rare variant studies are now being used to characterize the genetic diversity between individuals and may help to identify substantial amounts of the genetic variation of complex diseases and quantitative phenotypes. Family data have been shown to be powerful to interrogate rare variants. Consequently, several rare variants association tests have been recently developed for family‐based designs, but typically, these assume the normality of the quantitative phenotypes. In this paper, we present a family‐based test for rare‐variants association in the presence of non‐normal quantitative phenotypes. The proposed model relaxes the normality assumption and does not specify any parametric distribution for the marginal distribution of the phenotype. The dependence between relatives is modeled via a Gaussian copula. A score‐type test is derived, and several strategies to approximate its distribution under the null hypothesis are derived and investigated. The performance of the proposed test is assessed and compared with existing methods by simulations. The methodology is illustrated with an association study involving the adiponectin trait from the UK10K project. Copyright © 2015 John Wiley & Sons, Ltd.